InsiderTrades.com logo
John R. Desjarlais net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

John Desjarlais Biography and Net Worth

Executive Vice President, Research & Chief Scientific Officer of Xencor

Dr. Desjarlais oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates and has served as chief scientific officer since 2014. Prior to joining Xencor in 2001, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University, where he developed protein engineering methods. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais received a B.S. in physics from the University of Massachusetts and a Ph.D. in biophysics from Johns Hopkins University. He completed a post-doctoral fellowship at the University of California, Berkeley.

What is John R. Desjarlais' net worth?

The estimated net worth of John R. Desjarlais is at least $1.76 million as of November 11th, 2024. Dr. Desjarlais owns 200,104 shares of Xencor stock worth more than $1,758,914 as of May 12th. This net worth evaluation does not reflect any other investments that Dr. Desjarlais may own. Additionally, Dr. Desjarlais receives an annual salary of $748,650.00 as Executive Vice President, Research & Chief Scientific Officer at Xencor. Learn More about John R. Desjarlais' net worth.

How old is John R. Desjarlais?

Dr. Desjarlais is currently 60 years old. There are 4 older executives and no younger executives at Xencor. The oldest executive at Xencor is Dr. Nancy Valente M.D., Executive VP & Chief Development Officer, who is 65 years old. Learn More on John R. Desjarlais' age.

What is John R. Desjarlais' salary?

As the Executive Vice President, Research & Chief Scientific Officer of Xencor, Inc., Dr. Desjarlais earns $748,650.00 per year. There are 2 executives that earn more than Dr. Desjarlais. The highest earning executive at Xencor is Dr. Bassil I. Dahiyat Ph.D., Co-Founder, CEO, President & Director, who commands a salary of $1,070,000.00 per year. Learn More on John R. Desjarlais' salary.

How do I contact John R. Desjarlais?

The corporate mailing address for Dr. Desjarlais and other Xencor executives is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. Xencor can also be reached via phone at (626) 305-5900 and via email at investors@xencor.com. Learn More on John R. Desjarlais' contact information.

Has John R. Desjarlais been buying or selling shares of Xencor?

John R. Desjarlais has not been actively trading shares of Xencor during the past quarter. Most recently, John R. Desjarlais sold 68,684 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a transaction totalling $1,612,700.32. Following the completion of the sale, the vice president now directly owns 200,104 shares of the company's stock, valued at $4,698,441.92. Learn More on John R. Desjarlais' trading history.

Who are Xencor's active insiders?

Xencor's insider roster includes Bassil Dahiyat (CEO), John Desjarlais (Executive Vice President, Research & Chief Scientific Officer), Celia Eckert (Senior Vice President, General Counsel and Corporate Secretary), Kurt Gustafson (Director), Alan Montgomery (Director), and Allen Yang (CMO). Learn More on Xencor's active insiders.

Are insiders buying or selling shares of Xencor?

In the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 176,995 shares worth more than $3,994,070.52. The most recent insider tranaction occured on May, 2nd when EVP Nancy Valente sold 4,616 shares worth more than $50,914.48. Insiders at Xencor own 4.8% of the company. Learn More about insider trades at Xencor.

Information on this page was last updated on 5/2/2025.

John R. Desjarlais Insider Trading History at Xencor

See Full Table

John R. Desjarlais Buying and Selling Activity at Xencor

This chart shows John R Desjarlais's buying and selling at Xencor by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Xencor Company Overview

Xencor logo
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.
Read More

Today's Range

Now: $8.79
Low: $8.62
High: $9.18

50 Day Range

MA: $10.73
Low: $7.67
High: $13.90

2 Week Range

Now: $8.79
Low: $7.16
High: $27.24

Volume

130,655 shs

Average Volume

639,160 shs

Market Capitalization

$625.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99